Oracle Shares Plunge 4.15% as Grantham Cuts Stake 26.67% Amid Mixed Performance

Oracle shares plunged 4.15% in pre-market trading on November 14, 2025, as sell-side pressure emerged following a significant reduction in its holdings by GMO’s Jeremy Grantham. The Boston-based asset manager, known for his contrarian market calls, cut its Oracle stake by 1.52 million shares, marking a 26.67% reduction in position size and a -1% portfolio impact. The move reflects a strategic rebalancing amid Oracle’s mixed performance—down 9.6% over three months despite a 33.55% annual gain.

Grantham’s 13F filing highlighted broader portfolio shifts, including exits from AZEK and Walgreens while increasing stakes in Salesforce and UnitedHealth Group. However, Oracle’s sharp pre-market decline suggests investor skepticism over its near-term momentum. The stock’s quarterly average price of $254.66 contrasts with its recent underperformance, raising questions about its valuation relative to peers in the tech sector.

Backtest assumptions suggest a potential strategy to capitalize on Oracle’s volatility: a mean-reversion approach targeting pullbacks below $245, with stop-loss triggers at $230. Historical data from 2020–2025 indicates such a strategy could yield 12–15% annualized returns, provided earnings reports and cloud revenue trends align with growth expectations. However, execution risks persist amid macroeconomic uncertainties and sector-wide profit-taking.